Home Cart Sign in  
Chemical Structure| 145-42-6 Chemical Structure| 145-42-6

Structure of Taurocholic acid sodium
CAS No.: 145-42-6

Chemical Structure| 145-42-6

Taurocholic acid sodium

CAS No.: 145-42-6

Monosodium taurocholate is an agonist of GPBAR1 and is potential of the treatment of type 2 diabetes and obesity in rats.

Synonyms: Sodium taurocholate; N-Choloyltaurine sodium; TCA

4.5 *For Research Use Only !

Cat. No.: A198685 Purity: 95%

Change View

Size Price

US Stock

Global Stock

In Stock
10mg łÇǶÊÊ Inquiry Inquiry
50mg łÇÿ¶ÊÊ Inquiry Inquiry
1g ł§Ç¶ÊÊ Inquiry Inquiry
5g łîÿ¶ÊÊ Inquiry Inquiry
25g ł§îď¶ÊÊ Inquiry Inquiry
100g łÇ§ÇʶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 10mg

    łÇǶÊÊ

  • 50mg

    łÇÿ¶ÊÊ

  • 1g

    ł§Ç¶ÊÊ

  • 5g

    łîÿ¶ÊÊ

  • 25g

    ł§îď¶ÊÊ

  • 100g

    łÇ§ÇʶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Taurocholic acid sodium

CAS No. :145-42-6
Formula : C26H44NNaO7S
M.W : 537.68
SMILES Code : C[C@H](CCC(NCCS(=O)([O-])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C.[Na+]
Synonyms :
Sodium taurocholate; N-Choloyltaurine sodium; TCA
MDL No. :MFCD00150819

Safety of Taurocholic acid sodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Taurocholic acid sodium

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells >200 µM 24 hours TCA increased the number of HepG2 cells and induced cell death at high concentrations (>200 μM). Clin Mol Hepatol. 2023 Apr;29(2):465-481
JS-1 cells >200 µM 24 hours TCA significantly promoted JS-1 cell proliferation at high concentrations (>200 μM). Clin Mol Hepatol. 2023 Apr;29(2):465-481
LX-2 cells 12.5-200 µM 24 hours TCA dose-dependently stimulated HSC proliferation, with significant promotion at low concentrations (12.5-200 μM) in LX-2 cells. Clin Mol Hepatol. 2023 Apr;29(2):465-481
LX2NTCP+ cells 100 µM 45 minutes To assess TCA uptake in LX2NTCP+ cells and its effect on HSC activation, results showed TCA was internalized and increased αSMA expression. Gut. 2022 Jul;71(7):1373-1385
LX2 cells 100 µM 48 hours To evaluate the effect of TCA on LX2 cell activation, results showed TCA treatment increased αSMA expression, indicating HSC activation. Gut. 2022 Jul;71(7):1373-1385
Xenopus oocytes 1 mM 60 seconds To investigate the effect of taurocholic acid sodium on ENaC currents, results showed that taurocholic acid sodium increased the open probability of ENaC. J Physiol. 2022 Nov;600(21):4695-4711

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice C57BL/6J male mice Perfusion 1 mM Single administration, lasting 4 minutes To investigate the effect of taurocholic acid sodium on ENaC in mouse distal renal tubules, results showed that taurocholic acid sodium increased the open probability of ENaC. J Physiol. 2022 Nov;600(21):4695-4711
Rats Rat model with an extracorporal bile duct Intravenous infusion 500 μmol/kg/h Continuous infusion for 54 hours To study the feedback inhibition of bile acid synthesis by taurocholic acid sodium. Results showed that taurocholic acid inhibited bile acid synthesis only at a supraphysiological dose (500 μmol/kg/h), but not at a dose close to the initial bile acid secretion rate (300 μmol/kg/h). J Clin Invest. 1989 Jul;84(1):173-80

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04744103 Actinic Cheilitis PHASE4 WITHDRAWN 2023-09-15 QEII, Halifax, Nova Scotia, B3... More >>H 2Y9, Canada Less <<
NCT04823520 Melasma PHASE4 UNKNOWN 2022-09-30 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.86mL

0.37mL

0.19mL

9.30mL

1.86mL

0.93mL

18.60mL

3.72mL

1.86mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories